OS Therapies Inc., the champion in listeria-related cancer immunotherapies, is near to offshoot OS Animal Health, Inc. (OSAH) into a standalone public company to be registered on a national stock exchange to accelerate the internal business. OSAH is the company’s wholly owned ancillary that establishes OST-HER2 for canine osteosarcoma. The Company sees OSAH as a standalone public company listed on a U.S national stock exchange by next year. This will accelerate the business value of the OS Therapies.
The DVM, Animal Health Strategic Advisor for OS Therapies, Edward Robb, said, “Since being a part of the initiative to enhance the standard of care for dogs suffering from osteosarcoma for years, I’m grateful that OS Therapies has come up with the animal health program that will soon be a standalone. The standalone company will act as a separate, financed venture so that it gets the well-deserved attention that is needed. I’ll be in a major senior management level position with OS Animal Health.”
“Further, I’ll be helping the company to hire excellent leadership in the veterinary area to bolster the spectacular commercial launch. The launch will take place once the product gets a green signal from the mandated regulatory authorisations to relaunch in the United States region.”
Robb added, “As seen on the Towards Health page in the veterinary oncology market, the predicted growth rate is from $1.58 billion in 2024 to reach $4.77 billion by 2034. The market is initially characterised by the North American market, regarding its high expenditure and advanced veterinary infrastructure on pet healthcare. We have faith in the OST-HER2 potential as a molecularly focused advanced immunotherapy to later gain a position as the key player in that growth.”
OST-HER2 was popularly screened on the crucial acclaimed film named “Shelter Me: Cancer Pioneers”. The film was awarded the best Anthem Award for the ‘Documentary or Film under Awareness Categories, Health’ category and was further nominated for the Emmy Daytime Awards 2025 under the ‘Outstanding Daytime Special’ category.
MPH, CEO and Chairman of OS Therapies, Paul Romness, said, “We have invested the last several months collaborating with major opinion leaders, management candidates, strong investors, potential USDA-registered commercial manufacturers and regulatory experts. This pack of excellence will create the crucial mass that is essential to make this a standalone animal health venture, an outstanding venture.”
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
